Adaptive Biotechnologies Q2 revenue $71.6M (+22% YoY); MRD up 33%; raises FY MRD guidance; CSO transitions to consultant

Adaptive Biotechnologies Corp

Q2 revenue $71.6M (+22% YoY); MRD revenue $66.2M (+33% YoY); clonoSEQ volume 36,111 (+43% YoY).
Net loss $39.9M (incl. $23.7M loss on OrbiMed settlement); adjusted EBITDA loss improved to $0.7M from $7.2M.
Completed $345M zero-coupon convertible notes offering; repaid OrbiMed Purchase Agreement; cash $371.7M.
Raised FY 2026 MRD revenue guidance to $268M-$278M (from $260M-$270M); total opex guidance narrowed to $350M-$355M.
CSO and co-founder Harlan Robins transitions to strategic consultant role; no disagreements.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.